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Introduction:Status Epilepticus(SE) is a medical emergency associated with significant morbidity and 
mortality. Randomized controlled trials(RCTs) are important means in appraising therapeutic 
interventions. Evaluation of the reporting quality of RCTs regarding the use of second line 
antiepileptic drugs(AEDs) in SE treatment is insufficient. 
Purpose:The implementation of the CONSORT statement in the assessment of the reporting quality 
of RCTs for sodium valproate(VPA) in SE published from 2007 to 2018. 
Methods:A literature search was conducted in MEDLINE(PubMed) and Cochrane Library, as well as a 
manual search of cited references in the retrieved RCTs and meta-analyses. Our primary objective 
was to estimate the proportion of adherence to the CONSORT statement. Secondary objectives 
included the investigation of possible associations with the reporting quality of abstracts and journal 
impact factor(IF), plus the determination of the proportion of adherence per CONSORT-item. We 
additionally assessed the reporting quality of Pilot RCTs. 
Results:Seven eligible studies were identified. Mean adherence was 52.40% 
(sd=16.57,median=47%). According to non-parametric analysis, correlation between reporting 
quality of abstracts and articles was significant(Spearman's rho=0.829,p-value=0.021<0.05, Pearson’s 
r=0.737,p-value=0.059>0.05). Correlation between CONSORT adherence and journal ranking was 
insignificant (rho=0.571,p-value=0.180>0.05, r=0.627, p-value=0.183). Introduction and Discussion 
items were more adequately reported compared to methodological features and outcomes. 
CONSORT compliance between RCTs and Pilot RCTs(n=four, mean adherence=55.05%, 
sd=7.48,median=61.11%)  did not differ significantly according to Mann-Whitney-U test(p-
value=0.85). 
Conclusions:Adherence to the CONSORT statement abstains from the desirable standard. Principally, 
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Εισαγωγή:H επιληπτική κατάσταση(ΕΚ) αποτελεί ιατρικό επείγον που σχετίζεται με υψηλή 
νοσηρότητα και θνητότητα. Οι τυχαιοποιημένες κλινικές δοκιμές (ΤΚΔ) είναι εξαιρετικά σημαντικό 
εργαλείο στην αξιολόγηση των θεραπευτικών παρεμβάσεων. Η ποιότητα της καταγραφής στις ΤΚΔ 
που αφορούν τη χρήση δεύτερης γραμμής αντιεπιληπτικών στην ΕΚ δεν έχει εκτιμηθεί επαρκώς. 
Σκοπός:Η εφαρμογή της δήλωσης CONSORT στην αξιολόγηση της ποιότητας καταγραφής των 
δημοσιευμένων από το 2007 έως το 2018 ΤΚΔ που αφορούν στη χρήση Βαλπροϊκού Νατρίου(ΒΠΝ) 
στην ΕΚ. 
Μέθοδος:Πραγματοποιήσαμε αναζήτηση στις βάσεις δεδομένων MEDLINE(PubMed), και Cochrane 
Library, καθώς επίσης, χειροκίνητη αναζήτηση στη βιβλιογραφία κάθε ΤΚΔ και μετα-ανάλυσης που 
ανακτήθηκε. Ως πρωταρχικός στόχος τέθηκε ο υπολογισμός του ποσοστού εναρμόνισης κάθε ΤΚΔ 
με τη δήλωση CONSORT. Δευτερεύοντες στόχοι ορίστηκαν ο καθορισμός πιθανών συσχετίσεων με 
το ποσοστό συμμόρφωσης των περιλήψεων στην επέκταση της δήλωσης CONSORT για τις 
περιλήψεις και τον συντελεστή βαρύτητας περιοδικού, καθώς και ο προσδιορισμός του ποσοστού 
των μελετών που καταγράφουν το κάθε ζητούμενο. Επιπλέον, υπολογίστηκε η ποιότητα 
καταγραφής των Πιλοτικών ΤΚΔ. 
Αποτελέσματα:Εντοπίστηκαν επτά μελέτες που πληρούσαν τις προϋποθέσεις. Η μέση εναρμόνιση  
υπολογίστηκε 52.40%(τυπική απόκλιση=16.57,διάμεσος=47%). Ο μη παραμετρικός έλεγχος 
ανέδειξε σημαντική συσχέτιση μεταξύ της ποιότητας καταγραφής περιλήψεων και 
άρθρων(Spearman's rho=0.829,p-value=0.021<0.05, Pearson’s r=0.737,p-value=0.059>0.05). Δεν 
αναδείχθηκε σημαντική συσχέτιση με τον συντελεστή βαρύτητας των περιοδικών(rho=0.571,p-
value=0.180>0.05, r=0.627, p-value=0.183). Η καταγραφή ήταν αρτιότερη στα τμήματα εισαγωγή 
και συζήτηση σε σχέση με τη μεθοδολογία και την παρουσίαση των αποτελεσμάτων. Η ποιότητα 
καταγραφής δε διέφερε σημαντικά μεταξύ ΤΚΔ και Πιλοτικών ΤΚΔ(n=4, μέση 
εναρμόνιση=55.05%,τυπική απόκλιση=7.48,διάμεσος=61.11%) σύμφωνα με το Mann-Whitney-U 
test(p-value=0.85). 
Συμπεράσματα:To ποσοστό συμμόρφωσης στη δήλωση CONSORT απέχει από το επιθυμητό 








Λέξεις κλειδιά: επιληπτική κατάσταση, βαλπροϊκό νάτριο, δήλωση CONSORT, τυχαιοποιημένη 
κλινική δοκιμή,  
Institutional Repository - Library & Information Centre - University of Thessaly




Randomized Control Studies (RCTs) are the cornerstone of evidence-based medicine (1). Ensuring the 
implementation of high quality standards in RCTs is essential in order to obtain solid evidence and 
derive valid conclusions. On the contrary, low quality RCTs may distort the results of an intervention 
prompting into misguided clinical decisions (2, 3). 
The CONsolidated Standards Of Reporting Trials (CONSORT) statement was developed to improve 
the quality of reporting of RCTs (4, 5). It comprises of a 25-item checklist and a flow diagram that 
ensure clarity and completeness of reporting (6). Transparency of reporting is required for the reader 
to appraise the quality of the study and provides future researchers with the necessary information 
to replicate a study. Reports often omit important details. Deficient reporting likely reflects erratic 
conduction and commonly leads to misinterpretation of the study results (7).  
The CONSORT statement was initially introduced in 1996(8) and underwent 2 revisions, in 2001 (9) and 
2010 (10). The revisions were accompanied by a detailed explanation and elaboration document (11, 
12). The CONSORT statement is endorsed by many scientific journals in order to improve the quality 
of RCTs (13-15). Nonetheless it is important to remember that quality of reporting does not always 
align with methodological quality (16). 
Epilepsy is a chronic condition in which a person suffers from recurrent seizures. Seizures constitute 
episodes of excessive electrical activity in the brain resulting in dysfunction of the structures 
involved (17). Status epilepticus (SE) refers to seizures lasting more than 5 to 10 minutes or two or 
more consecutive seizures without recovery of full consciousness. A more practical approach 
suggests that SE is considered a situation in which seizure duration necessitates the use of 
antiepileptic drugs (AEDs). SE is officially classified into four categories, early SE (ErSE), established 
SE (EsSE), refractory SE (RSE) and super refractory SE (SRSE) (18). 
It is recommended that initial treatment of SE relies on benzodiazepines. Established SE is defined as 
SE refractory to benzodiazepine treatment. EsSE persists for more than 30 minutes and is usually 
associated with permanent neuronal injury. Treatment of established SE requires admission to an 
Intensive Care Unit (ICU) and deployment of second line AEDs which include phenytoin (PHT), 
sodium valproate (VPA), levetiracetam(LEV), lacosamide and phenobarbital. Refractory and super 
refractory SE refer to episodes that render the use of intravenous anaesthetics necessary (19, 20). 
SE is a medical emergency associated with significant morbidity and mortality (21). Favourable 
prognosis is directly correlated with rapid seizure termination. Undoubtedly, it is of utmost 
importance to determine the most effective treatment plan, which has yet to be accomplished. 
Major controversy arises with regards to the efficacy and tolerability of second line AEDs (22). As part 
of the effort to establish the most effective treatment plan, the number of studies testing VPA in SE 
is constantly increasing.  
Nevertheless, assessment of the reporting quality of the studies is insufficient. To our knowledge, 
although benzodiazepines (first line AEDs) have been appraised in terms of reporting quality (23, 24), 
our study is the first to endeavour the evaluation of the reporting quality of RCTs for one second line 
AED, VPA, in SE treatment. 
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We carried out a retrospective evaluation of RCTs on the subject of VPA use in the treatment of SE  
between January 1, 2007, and July 21, 2018.  
Search Method 
We performed a comprehensive search of the MEDLINE and Cochrane Library databases to identify 
all relevant RCTs published between January 1, 2007, and July 21, 2018. The search strategy used the 
MeSH terms ‘status epilepticus’ and ‘sodium valproate’ plus the terms ‘status epilepticus’, ‘epileptic 
status’, ‘valproate’ and ‘valproic acid’ as title or abstract words combined with the Boolean 
Operators ‘OR’ and ‘AND’. 
 (((((status epilepticus[MeSH Terms]) OR status epilepticus[Title/Abstract]) OR epileptic 
status[Title/Abstract]) AND ( "2007/01/01"[PDat] : "2018/07/21"[PDat] ))) AND ((((valproic 
acid[MeSH Terms]) OR valproate[Title/Abstract]) OR valproic acid[Title/Abstract]) AND ( 
"2007/01/01"[PDat] : "2018/07/21"[PDat] ))  
 The references quoted by retrieved RCTs as well as meta-analyses were manually searched. 
Eligibility Criteria 
We defined RCTs as prospective studies with random assignment of their human population to two 
or more intervention groups. We included reports that met the following criteria: (1) they were 
classified as RCTs (2) they were published from January 1, 2007 to July 21, 2018 (3) one intervention 
group was randomized to VPA (4) the population under research was people suffering from SE. 
Exclusion criteria included: (1) reports not published in English (2) unavailable full articles (3) studies 
performed in animals (4) pilot studies (5) conference abstracts (6) study protocols (7) other study 
designs (eg retrospective study design, prospective not randomized design) (8) retracted papers. 
We proceeded in a systematic review of all titles and abstracts retrieved. In case of inability to 
establish if a study met the inclusion criteria we reviewed the full text. 
Data Extraction 
The 2010 revised CONSORT statement comprises of 25 items, 12 of which are divided into 2 parts. 
Each of the 37 items was assessed equally by 1 point when adequately reported, 0 when either 
inadequately reported or absent and as not applicable according to certain features of the studies. 
Items reported more than once were assessed by 0 in case of inconsistency. Items composed of 2 or 
more sections were subdivided and valued equally (1/ number of sections) so as to assess the RCTs 
more accurately. Based on CONSORT 2010 explanation and elaboration document we decided to 
subdivide item 13a into 5 sections. Items 3b (changes to methods), 6b (changes to trial outcomes), 
7b (interim analyses and stopping guidelines), 11b (description of the similarity of interventions), 
12b (subgroup analyses and adjusted analyses), 14b (why the trial ended or was stopped), 18 (results 
of any other analyses performed) were not assessed in case of non-applicability. We determined the 
proportion of adherence to the CONSORT statement without taking not applicable items into 
consideration. Consequently, each study was rated against a different number of items.  
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Table 1 | CONSORT 2010 checklist of information to include when reporting a randomised trial (adaptation after the 
addition of subdivisions) 
Section/Topic 
Item 
No Checklist item  
Title and abstract 1a Identification as a randomised trial in the title 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance 
see CONSORT for abstracts) 
Introduction - Background 
and objectives 
2a Scientific background and explanation of rationale 
2b Specific objectives or hypotheses 
Methods  
Trial design 3a Description of trial design  Allocation ratio 
3b Important changes to methods after trial commencement (such as eligibility criteria), with 
reasons 
Participants 4a Eligibility criteria for participants 
4b Settings and locations where the data were collected 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how 
and when they were actually administered 
Outcomes 6a Completely defined pre-specified primary 
outcome measures, including how and when 
they were assessed 
Completely defined pre-specified secondary 
outcome measures, including how and when 
they were assessed 
6b Any changes to trial outcomes after the trial commenced, with reasons 
Sample size 7a How sample size was determined 
7b When applicable, explanation of any interim analyses and stopping guidelines 
Randomisation: 
Sequence generation 8a Method used to generate the random allocation sequence 
8b Type of randomisation; details of any restriction (such as blocking and block size) 
Allocation concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially 
numbered containers), describing any steps taken to conceal the sequence until interventions 
were assigned 
Implementation 10 Who generated the random 
allocation sequence  
Who enrolled participants   Who assigned participants 
to interventions 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care 
providers, those assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 
Statistical methods 12a Statistical methods used to compare groups 
for primary outcomes 
Statistical methods used to compare groups 
for secondary outcomes 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 
Results 






















by study group 
13b For each group, losses and exclusions after randomisation, together with reasons 
Recruitment 14a Dates defining the period of recruitment  Dates defining the period of follow-up 
14b Why the trial ended or was stopped 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether 
the analysis was by original assigned groups 
Outcomes and estimation 17a For each primary and secondary outcome, 
results for each group 
For each primary and secondary outcome, 
the estimated effect size and its precision  
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, 
distinguishing pre-specified from exploratory 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT 
for harms) 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, 
multiplicity of analyses 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other 
relevant evidence 
Other information 
Registration 23 Registration number and name of trial registry 
Protocol 24 Where the full trial protocol can be accessed, if available 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 
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Item 1b (Structured summary) was assessed separately based on the CONSORT for Abstracts 
extension (25), which comprises of 17 items. A 16-item version was deployed after the removal of the 
contact details item (specific to conference abstracts). 3 items were subdivided into 2 sections each 
valued with ½. Reported items inconsistent with the full text were assessed by 0. Item 1b was 
assessed by 1 when ≥8 of the 16 items were satisfied. 
Table 2 | Items to include when reporting a randomized trial in a journal or conference abstract 
Item Description Subdivisions 
Title  Identification of the study as randomized  
Authors * Contact details for the corresponding author  




  Participants Eligibility criteria for participants and the settings where the 
data were collected 
1)eligibility criteria for participants 
2)settings where the data were 
collected 
  Interventions Interventions intended for each group  
  Objective Specific objective or hypothesis  
  Outcome Clearly defined primary outcome for this report  
  Randomization How participants were allocated to interventions  
  Blinding (masking) Whether or not participants, care givers, and those 
assessing the outcomes were blinded to group assignment 
 
Results 
  Numbers randomized Number of participants randomized to each group  
  Recruitment Trial status 1)recruitment status 
2)follow up status 
  Numbers analysed Number of participants analysed in each group  
  Outcome For the primary outcome, a result for each group and the 
estimated effect size and its precision 
1)a result for its group 
2)the estimated effect size and its 
precision 
  Harms Important adverse events or side effects  
Conclusions General interpretation of the results  
Trial registration Registration number and name of trial register  
Funding Source of funding  
*this item is specific to conference abstracts 
Further information collected included journal ranking for the publication year (according to the 
Journal IF published each summer by Clarivate Analytics (Thomson Reuters) via Journal Citation 
Reports), date of publication, CONSORT endorsement by the corresponding journal, country of 
origin, implementation of multicentre design, sample size, interventions assigned, prior use of first 
line treatment and targeted age group. 
Due to the comparable number of retrieved RCTs and Pilot or Feasibility Trials we additionally 
decided to determine the proportion of adherence of pilot studies to the CONSORT extension for 
Pilot and Feasibility Trials(26) (26-item checklist). Evaluation was conducted on the same principles 
applied to the evaluation of RCTs. A 15-item checklist was utilised for the assessment of the item 
1b(structured summary) and a threshold of 7.5/15 was set for the item to be considered as 
reported.   
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Our primary objective was to estimate the proportion of adherence to the CONSORT statement for 
each RCT. We describe the mean and median adherence, the standard deviation (SD), the minimum 
and maximum adherence.  
Secondary objectives included the investigation of correlations between adherence to the CONSORT 
statement and adherence to the CONSORT extension for abstracts as well as Journal IF for the 
respective publication year. Furthermore, we determined the proportion of RCTs reporting each 
CONSORT-item. Additionally, we assessed the reporting quality of Pilot studies and proceeded to 
compare CONSORT compliance between RCTs and Pilot trials. 
Statistical Analysis 
All statistical analyses were performed with SPSS Statistics Software Version 24. After calculating 
statistic measures of central tendency and dispersion, we proceeded to analysis of correlations 
through calculation of the Spearman's rank correlation coefficient (Spearman’s rho, non parametric) 
and graphical presentation on scatter plots. In case of normally distributed data (according to the 
Shapiro-Wilk test which is superior to the Kolmogorov-Smirnov test for small samples)(27) we 
additionally determined the Pearson Correlation Coefficient (Pearson’s r). Comparison between RCTs 
and Pilot trials was carried out through Mann-Whitney U test (in case of normality, independent-
samples t-test was also calculated).  A p-value of <0.05 was set to be significant.  
Results 
The literature search identified 404 studies. The manual search did not provide us with additional 
RCTs. We meticulously screened all titles and abstracts retrieved and full texts when necessary. 7 
studies (28-34) were considered eligible for our review and are included in the current study. The main 
characteristics of the studies are presented at table 3. 
Table 3 I Study characteristics 
Study Amiri at al Su et al Chitsaz et al Malamiri et 
al 
Gilad et al Mehta et al Agarwal et 
al 




§ 1.982 2.317 1.240 1.815 
CONSORT 
endorsement** 
Yes Yes Yes Yes Yes Yes No 








Sample size 110 73 30 60 74 40 100 
Interventions VPA – PHT VPA - 
Phenobarbital 
VPA - PHT VPA - 
Phenobarbital 
VPA - PHT VPA - 
Diazepam 
VPA - PHT 
Initial use of first line 
AEDs(Benzodiazepines) 
Yes Yes Yes Yes No Yes Yes 




No Yes No No No No No 
Population Adults Adults Adults and 
Children 
Children Adults Children Adults and 
Children 
* according to Journal IF published each summer by Clarivate Analytics (formerly Thomson Reuters)  via Journal Citation 
Reports for the publication year                                                                                                                                                                    
**according to the presently provided instructions to authors by each journal                                                                
†
concerning primary outcome                                                                                                                                                        
††
according to Journal IF published in year 2018 by Clarivate Analytics (formerly Thomson Reuters)  via Journal Citation 
Reports which provides 2017 data. The 2018 data will be made available in the 2019 Journal Citation Reports release.                                         
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emerging source citation index since 2015 [a new database within Clarivate Analytics’ (formerly Thomson Reuters) Web of 
Science]. Journals indexed in the ESCI will not receive IF. However, the citations from ESCI will be included in the citation 
counts for the Journal Citation Reports                                                                                                                                                                  
§§
according to author information (not specified in the text) 
 


















Our primary purpose was to establish the proportion of consort adherence for each RCT. The 
following results were obtained:  
Amiri at al: (14.10/30, 47%), Su et al (23.43/30, 78.1%), Chitsaz et al (10.60/32, 33.16%), Malamiri et 
al (21.60/30, 72%), Gilad et al (13.60/32, 42.5%), Mehta et al: (16.6/32, 51.86%), Agarwal et al: 
(13.50/32, 42.19%) 
The mean CONSORT adherence was calculated at 52.40% with sd=16.57. The median was 47% and 
the minimum and maximum adherence 33.16% and 78.1% respectively. 
Adherence per consort item was evaluated (table 4). Several items were assessed as not applicable 
overall (3b, 6b, 7b, 13b, 14b). Reporting of items 11b and 18 (subgroup analyses and adjusted 
analyses), 17b (both absolute and relative effect sizes) and 11b (applicable in solely one study) was 
null. Items 23 and 24 (trial registration and protocol), 13b (losses and exclusions after 
Records identified through database searching 
N=404 
No additional candidates 
emerged from manual search 
 
Records after duplicates removed 
N=373 
Records excluded 
-not related                               
-other study designs                
-not in English                           
-unavailable full articles          
-animals studies                        
-pilot studies(4)                                
-conference abstracts              
-study protocols                                  
N=360 
RCTs included in the review 
N=7 
Full texts assessed for eligibility 
N=13 
1 retracted, 4 retrospective, 1 prospective non-
randomized 
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randomisation), as well as 1b (evaluated according to CONSORT for Abstracts extension) were 
significantly underreported. As regards to item 10, two sections were completely omitted and 
section ‘Who assigned participants to interventions’ was reported in only one study. In contrast, 
items 2a and 2b (background and objectives), 5 (interventions) and 16 (number of participants 
included in each analysis) were reported in all 7 studies. Inconsistencies between abstract and full 
article reporting were detected in 2 studies (regarding eligibility criteria and primary outcome 
definition), whereas in 1 study’s interpretation was not consistent with the results. 













1a 57.14 0 8a 28.57 0 15 42.86 0 
1b 14.3 0 8b 57.14 0 16 100 0 
2a 100 0 9 28.57 0 17a 42.86 0 
2b 100 0 10 4.76 0 17b 0 0 
3a 71.43 0 11a 57.14 0 18 0 3 
3b - 7 11b 0 6 19 85.71 0 
4a  71.43 0 12a 71.43 0 20 42.86 0 
4b 71.43 0 12b 0 3 21 85.71 0 
5 100 0 13a 65.71 0 22 85.71 0 
6a 57.14 0 13b 14.3 0 23 14.3 0 
6b - 7 14a 64.27 0 24 14.3 0 
7a 28.57 0 14b - 7 25 42.86 0 
7b - 7  
*the denominator is determined by the trials in which the item is applicable 
Participants flow was not illustrated in any of the studies by a flow diagram. Although, all 7 studies 
presented the number of participants randomized, treated as planned and analyzed, only one study 
reported the number of people evaluated for enrolment and participants followed up as planned.  
Figure 2 | CONSORT 2010 Flow Diagram 
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Figure 3 Compliance per CONSORT item 
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The Spearman's rho between CONSORT and journals’ IF was (0.571, p-value=0.180>0.05), which is 
suggestive of a moderate positive correlation, but is not statistically significant. We determined the 
Pearson’s r (IF were normally distributed) without taking the study of Chitsaz et al into consideration 
(ESCI). The result was not statistically significant (0.627, p-value=0.183). 
Figure 4 I Trends between Article and Abstract reporting quality / reporting quality and journal ranking 
 
In the second chart the study of Chitsaz at al is featured. Since it was published in a journal indexed in the ESCI it was 
conventionally attributed an impact factor of 0. 
 
Reporting Quality of Abstracts 
We evaluated the reporting quality of each abstract based on the CONSORT for Abstracts extension. 
The following results were obtained: mean=41.07, sd=11.04, median=43.75 min&max=18.75&53.13 
Amiri at al: (6/16, 37.5%), Su et al (7.5/16, 46.86%), Chitsaz et al (3/16, 18.75%), Malamiri et al 
(8.5/16, 53.13%), Gilad et al (7/16, 43.75%), Mehta et al: (7.5/16, 46.86%), Agarwal et al: (6.5/16, 
40.63%) 
The Spearman's rho between CONSORT adherence and adherence to the CONSORT extension for 
abstracts was calculated (0.829, p-value=0.021<0.05). The result was indicative of a strong positive 
correlation between abstract and article reporting quality and was statistically significant. Pearson’s 
r (Shapiro-Wilk test compatible with normal distribution for both variables) was also determined 
(0.737, p-value=0.059>0.05), but the result was not statistically significant. 
Reporting Quality of Pilot Trials 
 
The literature search we performed provided four Pilot trials (35-38). CONSORT compliance was 
assessed:  
Misra et al 2006: (10.83/33, 32.82%), Chen et al: (20.5/33, 62.12%), Mundlamuri et al (19.83/33, 
60.1%), Misra et al 2017 (21.5/33, 65.15%) 
The mean CONSORT adherence was calculated at 55.05% with sd=7.48. The median was 61.11% and 
the minimum and maximum adherence 32.82% and 65.15% respectively. Item 1b was appraised as 
reported in only one trial (with a score of 7.5/15).  
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Mann-Whitney U test determined than CONSORT adherence was similar between RCTs and Pilot 
trials, p-value=0.85 (according to Shapiro-Wilk test figures from Pilot trial assessment were not 
normally distributed, p-value=0.45). 
Conclusions 
We evaluated the reporting quality of RCTs for sodium valproate in status epilepticus according to 
the 2010 CONSORT statement. Our review included all RCTs published between 2007 and 2018. 7 
eligible studies were assessed for adherence to the CONSORT statement. The overall reporting 
quality was rather poor (52.40%) with solely 2 studies reporting above 70% of the CONSORT items. 
Reporting essential CONSORT items, relating to methodological features and results, was notably 
insufficient, complicating the interpretation of the studies. In contrast, elaboration of the study 
background and discussion of the study results were sufficiently reported. 
Our study attempted to investigate correlations between adherence to the CONSORT statement and 
adherence to the CONSORT extension for abstracts as well as journal ranking. It is crucial that 
abstracts of RCTs constitute well structured and accurate summaries of the study. Readers 
commonly decide to acquire or not articles based on the quality of abstracts, owing to the 
overabundance of publications in most fields (39). It is not our purpose to determine if there is a need 
for optimisation in the CONSORT compliance of abstracts, but rather to establish if the reporting 
quality of abstracts is indicative of the reporting quality of RCTs. Our analysis included both 
parametric and non-parametric methods. Despite the fact that data followed normal distribution 
according to the Shapiro-Wilk test, it would not be prudent to ignore the small sample size. Results 
from both analyses were suggestive of strong positive correlation, with Spearman’s rho reaching 
statistical significance and Pearson’s r falling short of significance. The study of Jeroen P. M. Peters et 
al (40) determined CONSORT compliance of both full-texts and abstracts in otorhinolaryngologic 
literature, but did not investigate for correlations between them. 
IF is considered by many as a marker of journal quality and consequently, article quality (41). 
Correlation between adherence to the CONSORT statement and journals ranking was also 
determined by both parametric and non-parametric methods, both of which were indicative of 
moderate correlation, but without achieving statistical significance. This correlation has been 
studied by multiple reviews (42-46), some of which were able to identify significant correlation (44-46). 
Pilot trials are considered preliminary studies (47). They are conducted on a smaller scale than the 
main study in order to assess the feasibility (design, recruitment, randomization, blinding) of a larger 
full-scale study. At the same time, researchers gather evidence regarding the efficacy and adverse 
effects of an intervention (48). Therefore it is comprehensible that transparent reporting of Pilot RCTs 
is of crucial importance for researchers to recreate a concluding study or to assemble evidence as 
part of a meta-analysis. The literature search we performed identified four Pilot studies, a number of 
studies comparable to the number of RCTs. Therefore, we decided to appraise the reporting quality 
of the Pilot trials retrieved. A slightly greater, but insignificant, CONSORT compliance was observed. 
Many other parameters have been proposed as possible determinants of the reporting quality of 
RCTs. Liu et al (42), as well as Plint et al (49) analysed the role of CONSORT endorsement and concluded 
that reporting quality is superior in journals that endorse the CONSORT statement . On the grounds 
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that scientific collaboration is sometimes accountable for higher quality studies(50) the number of 
authors has been proposed as a possible determinant of reporting quality(43, 46), without significant 
results supporting this claim. Stevanovic et al (44) obtained significant results from the correlation of 
CONSORT adherence and citation count per article. Single or multi-centre design (50) is not considered 
an important factor. Sample size(42,50), publication date(43, 51) and funding of a study(42, 50, 51) have also 
been analysed, with outcomes being contradictory.  
Reporting of the methodological items is probably the most crucial segment of the CONSORT 
statement. There is a number of studies that focuses primarily on methodological features since 
their optimization is considered most important(52-54). We obtained disappointing results regarding 
reporting quality of methodological features, which appears to be a scourge on reporting quality of 
RCTs in general. 
Wu et al(23) and McMullan et al(24) made an effort to review the reporting quality of RCTs for 
benzodiazepines (first line AEDs) in SE as part of meta-analyses. Wu et al reviewed studies between 
lorazepam or diazepam from 1966 to February 2014. 6 eligible studies were assessed based on a 22 
item list and the proportion of reported items (10, 11, 13, 13, 15, 18) was assessed as satisfactory. 
McMullan et al reviewed RCTs between midazolam and diazepam. The CONSORT reporting tool was 
deployed in a form of a 30-item list and a threshold score of at least 20 was established for inclusion. 
Among the 14 eligible studies 8 were attributed a CONSORT score of 15-19, whereas 6 were 
attributed a CONSORT score above 20 (22, 23, 24, 26, 27, 28). Both studies recorded superior 
reporting qualities in comparison with our findings. 
To our knowledge, our study is the first to assess the reporting quality of studies in the field of 
second line AEDs in the treatment of SE. We divided each CONSORT item into sections in order to 
establish a more accurate reporting tool. It is appropriate to point out that our study has certain 
limitations. First of all, our research provided a small number of RCTs. Secondly, each RCT was 
assessed by a single researcher. In addition to that, the researcher was not blinded to information in 
regards to authorship, country of origin and journal in which the article was published. Furthermore, 
we reviewed exclusively studies published in English. Having said all these, we would like to highlight 
the importance of carrying out a study for evaluation of the reporting quality of RCTs in their initial 
form of submission in comparison with the published form, so as to investigate the improvement of 
reporting thanks to the revisions prior to publication. 
It is of critical importance to keep in mind that reporting quality is not identical to procedural quality. 
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